Long Noncoding RNAs: Clarity or Confusion?
Because They Are Such Elusive Prey, lncRNAs Have Yet to Emerge as Therapeutic Targets
Markets Expand for Single-Use Bioreactors
Biobags Offer Advantages Over Fixed-Tank Systems
The Challenges of Harmonizing Biomarker Data
Why Trial Success Depends on It
Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
For full access to this article login to GEN Select now.
Developing Next-Gen Conjugate Vaccines
Public Health Concerns Mandate New Approaches to Combat Bacterial Pathogens
- The vaccine market experienced significant growth over the last decade, with global revenues exceeding $24 billion in 2010, up from $7 billion in 2004. Major growth drivers were the increasing awareness of vaccine-preventable diseases as well as the introduction of new products. Within this growing market, glycoconjugate vaccines for ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.